Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309438 · ClinicalTrials.gov registry record · Phase 1
A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
A Phase 1 study of Healthy and Renal Insufficiency, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 4
- Study locations
NCT01309438: Completed Phase 1 study of Healthy and Renal Insufficiency, sponsored by Janssen Research & Development.
NCT01309438 is a Phase 1 study of Healthy and Renal Insufficiency that has completed, run by Janssen Research & Development. The registered enrollment target is 29 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01309438, a Phase 1 study of Healthy and Renal Insufficiency, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban when administered with erythromycin to study participants with mild or moderate renal impairment compared to the pharmacokinetics and pharmacodynamics of rivaroxaban administered to study participants with normal renal function.
Conditions Studied
Interventions
- DRUG Rivaroxaban (normal renal function)
- DRUG Rivaroxaban (mild and moderate renal impairment)
- DRUG Erythromycin (normal renal function)
- DRUG Erythromycin (mild and moderate renal function)
Study Locations (4)
Minnesota
- - Minneapolis
- - Saint Paul
Florida
- - Orlando
Tennessee
- - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT01309438 record still lists
NCT01309438 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Rivaroxaban (normal renal function) is the first listed.
NCT01309438 reports a single indexed study location in Minnesota, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01309438 about?
NCT01309438 is a clinical study titled "A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function". The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban when administered with erythromycin to study participants with mild or moderate renal impairment compared to the pharmacokinetics and pharmacodynamics of rivaroxaban administered to study participants w...
What is the current status of trial NCT01309438?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2011-02. Estimated completion is 2012-03.
What conditions does trial NCT01309438 study?
This clinical trial studies the following conditions: Healthy, Renal Insufficiency.
What interventions are being tested in trial NCT01309438?
The interventions under investigation include: Rivaroxaban (normal renal function) (DRUG), Rivaroxaban (mild and moderate renal impairment) (DRUG), Erythromycin (normal renal function) (DRUG), Erythromycin (mild and moderate renal function) (DRUG).
Who is sponsoring clinical trial NCT01309438?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01309438 being conducted?
This trial has 4 study locations across Florida, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01309438's enrollment target sits among peer trials
29 729th of 1090 higher than 356 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia